Developer docs
API playgroundTry for free, no card

Search company profiles

Byonyks Medical Devices, Inc.

Full company profile

uuid0000v2s

Namestring
Byonyks Medical Devices, Inc.
Legal namestring
Byonyks Medical Devices, Inc.
Websiteurl
byonyks.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Byonyks Medical Devices, Inc. is a privately held medical device company founded in 2019 and headquartered in Itasca, Illinois, that develops automated peritoneal dialysis (APD) cyclers for home-based treatment of end-stage kidney disease (ESKD). Its flagship product, the X-1 APD Cycler, received FDA 510(k) clearance in May 2025, making Byonyks only the third company globally to obtain this clearance. The device delivers bloodless, needle-free dialysis with a touchscreen interface, battery backup, and built-in safety systems including pressure monitoring, leak detection, and emergency shutdown; the company is also developing X2 and X3 next-generation devices featuring biocompatible, acid-free dialysate technology. Byonyks has assembled a leadership team drawn heavily from the dialysis industry, including Rod Kenley (100+ dialysis patents, 40+ years of experience) and other veterans whose prior work contributes to devices used by 62% of U.S. peritoneal dialysis patients.

The company operates an ISO 13485-certified manufacturing facility in Punjab, Pakistan, with R&D centers in Chicago and Lahore, and planned dialysate and tubing/assembly plants in Hyderabad and Gujarat, India. Its revenue model combines hardware sales of the X-1 cycler, recurring revenue from consumables and dialysate, and international licensing, the last of which has supported 10,000+ overseas therapies to date. Distribution follows a dual approach: direct enterprise field sales for the U.S. market (initial rollout in California, Texas, and Illinois beginning February 2026) and channel/licensing partnerships for international markets across South Asia, the Middle East, East Africa, and Europe. Target customers are dialysis providers, nephrologists, and healthcare systems seeking cost-effective home dialysis technology, supported by the U.S. federal mandate to move 80% of ESKD patients to home dialysis or transplant.

Byonyks has raised approximately $21.6M across five funding rounds between 2021 and 2025, including a $1M Form D debt offering in January 2023. The company holds Scientific Advisory Board relationships with former International Society for Peritoneal Dialysis (ISPD) presidents and a clinical partnership with Dr. Andrew King's Home Dialysis Therapies for early U.S. adoption. Strategic positioning targets the $120B global dialysis market and $44B U.S. market, where Byonyks contends that only 13% of U.S. dialysis patients are currently on home therapy despite government targets of 80%, and where it competes against a historical two-player duopoly of incumbent providers.

Short descriptiontext

Byonyks Medical Devices is a Chicago-area medical device company founded in 2019 that develops FDA-cleared, needle-free automated peritoneal dialysis cyclers for home treatment of end-stage kidney disease, serving dialysis providers, nephrologists, and healthcare systems across the U.S., South Asia, and other international markets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersItasca, United States
HQ citystring
Itasca
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
peritoneal dialysis devices, automated dialysis cyclers, home dialysis equipment, medical device manufacturing, renal replacement therapy
Industry3 codes
1Peritoneal Dialysis (PD) Systems & Supplies
CodeHLAHAKABPrimaryYes
2Home Dialysis Equipment & Remote Monitoring
CodeHLAHAKAGPrimaryNo
3Kidney & Dialysis Remote Care (CKD/ESRD monitoring, home dialysis support)
CodeHLALAFACPrimaryNo
NAICS code3 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing3345
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Medical Devices
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Medical Device Sales
TypeHardware Sales
Description

Sale of X-1 APD Cycler and future X2 & X3 devices for home peritoneal dialysis. The devices are sold directly to healthcare providers and dialysis centers.

byonyks.com
2Consumables and Dialysate
TypeSubscription Recurring
Description

Recurring revenue from consumables including dialysate solutions and tubing for dialysis treatments. The company is also developing on-demand dialysate production technology.

byonyks.com
3Overseas Licensing
TypeLicensing Royalties
Description

Revenue from licensing the technology internationally, demonstrated by 10,000+ successful therapies through overseas licenses.

byonyks.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1SEC filing indicates minimum investment of $25,000
ModelOtherBilling cadencePay-as-you-go
Notes

Byonyks filed a Form D notice of exempt offering of securities involving debt securities that raised $1,000,000 with a planned minimum investment of $25,000.

sec.gov
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Byonyks Medical Devices designs, manufactures, and distributes the FDA 510(k)-cleared X-1 Automated Peritoneal Dialysis (APD) Cycler for home-based treatment of end-stage kidney disease. The device delivers bloodless, needle-free dialysis with a touchscreen interface, battery backup, and integrated safety systems, targeting dialysis providers, nephrologists, and healthcare systems. The company is also developing next-generation X2 and X3 devices featuring biocompatible, toxin-free dialysate and on-demand dialysate production technology.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 10% higher survival rate with peritoneal dialysis vs in-center hemodialysis (U.S. Renal Data System)
+3 more records
Product overview1 text field

Byonyks Medical Devices, Inc. is a medical device company focused on home-based peritoneal dialysis solutions. The company has developed the X-1 APD Cycler as its flagship FDA 510(k)-cleared product, an automated peritoneal dialysis machine designed for home use that offers needle-free, bloodless dialysis therapy. The company is also developing X2 and X3 devices as next-generation products to further advance peritoneal dialysis technology. Together, these products aim to disrupt the $120 billion dialysis industry by offering more affordable, patient-friendly, and biocompatible dialysis solutions.

Product and service4 records
1Byonyks X-1 APD Cycler
CategoryAutomated Peritoneal Dialysis Device
Description

FDA 510(k)-cleared automated peritoneal dialysis (APD) cycler designed for home use by ESKD patients. Warms dialysis fluid to body temperature, operates needle-free, includes battery backup for uninterrupted therapy, features a touchscreen interface with built-in safety systems (pressure monitoring, leak detection, intelligent alarms, emergency stop), and is sold to dialysis providers, hospitals, and home dialysis programs.

2Byonyks X2 & X3 Next-Generation Peritoneal Dialysis Devices
CategoryAutomated Peritoneal Dialysis Device
Description

Next-generation peritoneal dialysis devices in development designed to deliver ultra-pure, biocompatible, non-inflammatory dialysis solutions. The combination of X2 and X3 devices is intended to reduce proven inflammatory mediators, allow customization of glucose and bicarbonate concentrations, reduce peritonitis risk, and significantly reduce plastic medical waste compared to typical home PD systems.

3Dialysate Solutions and Dialysis Consumables
CategoryDialysis Consumables
Description

Recurring consumables for dialysis treatments, including dialysate solutions and tubing used with the X-1 APD Cycler. Includes development of on-demand dialysate production technology aimed at lowering per-treatment cost and supporting home PD adoption in markets with limited supply chains.

4Overseas Dialysis Technology Licensing
CategoryTechnology Licensing
Description

International licensing of Byonyks' dialysis technology to regional partners and distributors, evidenced by 10,000+ successful therapies delivered through overseas licenses before U.S. commercialization. Provides access to South Asia, Middle East, East Africa, and European markets where APD availability has historically been limited.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Dr. Andrew King, Byonyks' Chief Medical Officer for North America, founded Home Dialysis Therapies in San Diego. This partnership provides clinical expertise and early adopter validation for Byonyks' APD technology, with Denise Barnes R.N. helping establish home-only facilities under this partnership.

2Kidney Beyond Borders
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partnership with Dr. Irfan Munir, Founder & President of Kidney Beyond Borders, for expanding access to dialysis care globally through collaborative initiatives and shared learning.

byonyks.com
Strategic tierCoreTypeTechnology or Integration
Description

Obtained official IEC certification from SGS in October 2023, an essential regulatory milestone for international market access and product safety compliance.

Strategic tierCoreTypeTechnology or Integration
Description

Obtained IEC approval from TUV SUD Minnesota in 2023, supporting regulatory compliance for the X-1 APD Cycler.

Strategic tierCoreTypeTechnology or Integration
Description

FiLab France approved biocompatibility tests in July 2023, a critical step in regulatory approval process for medical devices.

Strategic tierCoreTypeTechnology or Integration
Description

HTW China electrical testing lab approved in September 2023, supporting global regulatory compliance for the X-1 device.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Baxter is the dominant U.S. APD cycler manufacturer (HomeChoice, Amia systems) and the primary incumbent Byonyks must displace. Same product category (home peritoneal dialysis cyclers), same target customers (dialysis providers, nephrologists, ESKD patients), and overlapping direct-sales channels to hospitals and clinics.

TypeDirect peer
Description

Fresenius manufactures the sleep.safe harmony APD cycler and operates the largest U.S. dialysis clinic network (FMCNA), making it both a direct device competitor and a captive customer ecosystem. Directly comparable on product, market, and end-user.

TypeEmerging player
Description

Outset Medical's Tablo is a home-use hemodialysis system targeting the same shift to home-based renal care that Byonyks addresses. While hemodialysis rather than peritoneal, both pursue home dialysis economics, payer reform incentives, and inpatient-to-home care migration.

TypeEmerging player
Description

Quanta develops a portable hemodialysis device (SC+) for home and clinic use, targeting the same broader market of patients seeking home-based renal replacement therapy. Comparable on mission and home dialysis focus though different modality (HD vs PD).

TypeBroad incumbent
Description

DaVita is the largest U.S. dialysis services provider with extensive home dialysis programs. As a key customer of APD cyclers, it is a primary target buyer for Byonyks' X-1 system and benefits from the same regulatory and policy tailwinds.

TypeBroad incumbent
Description

B. Braun manufactures the dialog+ hemodialysis system and offers peritoneal dialysis consumables and equipment. While more diversified, B. Braun competes in the renal care space and is a relevant incumbent across PD and HD products.

TypeBroad incumbent
Description

NxStage pioneered home hemodialysis (System One) and is now part of Fresenius. It represents the home dialysis shift that Byonyks also targets and competes with for clinical mindshare and home dialysis program adoption.

TypeRegional player
Description

Terumo offers peritoneal dialysis products and dialysate solutions in Asia and other international markets, overlapping with Byonyks' overseas licensing footprint and serving comparable ESKD patient populations in geographies where the U.S. company is also expanding.

TypeEmerging player
Description

DEKA partnered with Baxter on APD technology and continues to develop next-generation peritoneal and hemodialysis systems. It represents the type of engineering-driven entrant pursuing innovation in the home dialysis category.

TypeBroad incumbent
Description

U.S. Renal Care is a mid-sized dialysis services provider with growing home dialysis programs, making it a target customer for Byonyks' X-1 cycler and a comparable channel partner in the shift toward home-based renal care.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Byonyks Medical Devices, Inc.

Medical Devicesbyonyks.com

Byonyks Medical Devices is a Chicago-area medical device company founded in 2019 that develops FDA-cleared, needle-free automated peritoneal dialysis cyclers for home treatment of end-stage kidney disease, serving dialysis providers, nephrologists, and healthcare systems across the U.S., South Asia, and other international markets.

What Byonyks Medical Devices, Inc. does

Byonyks Medical Devices, Inc. is a privately held medical device company founded in 2019 and headquartered in Itasca, Illinois, that develops automated peritoneal dialysis (APD) cyclers for home-based treatment of end-stage kidney disease (ESKD). Its flagship product, the X-1 APD Cycler, received FDA 510(k) clearance in May 2025, making Byonyks only the third company globally to obtain this clearance. The device delivers bloodless, needle-free dialysis with a touchscreen interface, battery backup, and built-in safety systems including pressure monitoring, leak detection, and emergency shutdown; the company is also developing X2 and X3 next-generation devices featuring biocompatible, acid-free dialysate technology. Byonyks has assembled a leadership team drawn heavily from the dialysis industry, including Rod Kenley (100+ dialysis patents, 40+ years of experience) and other veterans whose prior work contributes to devices used by 62% of U.S. peritoneal dialysis patients.

The company operates an ISO 13485-certified manufacturing facility in Punjab, Pakistan, with R&D centers in Chicago and Lahore, and planned dialysate and tubing/assembly plants in Hyderabad and Gujarat, India. Its revenue model combines hardware sales of the X-1 cycler, recurring revenue from consumables and dialysate, and international licensing, the last of which has supported 10,000+ overseas therapies to date. Distribution follows a dual approach: direct enterprise field sales for the U.S. market (initial rollout in California, Texas, and Illinois beginning February 2026) and channel/licensing partnerships for international markets across South Asia, the Middle East, East Africa, and Europe. Target customers are dialysis providers, nephrologists, and healthcare systems seeking cost-effective home dialysis technology, supported by the U.S. federal mandate to move 80% of ESKD patients to home dialysis or transplant.

Byonyks has raised approximately $21.6M across five funding rounds between 2021 and 2025, including a $1M Form D debt offering in January 2023. The company holds Scientific Advisory Board relationships with former International Society for Peritoneal Dialysis (ISPD) presidents and a clinical partnership with Dr. Andrew King's Home Dialysis Therapies for early U.S. adoption. Strategic positioning targets the $120B global dialysis market and $44B U.S. market, where Byonyks contends that only 13% of U.S. dialysis patients are currently on home therapy despite government targets of 80%, and where it competes against a historical two-player duopoly of incumbent providers.

Byonyks Medical Devices, Inc. firmographics

Firmographics
Name
Byonyks Medical Devices, Inc.
Legal name
Byonyks Medical Devices, Inc.
Website
https://byonyks.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
51–100 employees
Short description
Byonyks Medical Devices is a Chicago-area medical device company founded in 2019 that develops FDA-cleared, needle-free automated peritoneal dialysis cyclers for home treatment of end-stage kidney disease, serving dialysis providers, nephrologists, and healthcare systems across the U.S., South Asia, and other international markets.
Ownership category
akta.pro rank

Byonyks Medical Devices, Inc. industry classification

Industry
Product category
Medical Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
SIC
Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro primary industry
Peritoneal Dialysis (PD) Systems & Supplies (HLAHAKAB)
akta.pro secondary industries
Home Dialysis Equipment & Remote Monitoring (HLAHAKAG), Kidney & Dialysis Remote Care (CKD/ESRD monitoring, home dialysis support) (HLALAFAC)

Keywords

  • Peritoneal dialysis devices
  • Automated dialysis cyclers
  • Home dialysis equipment
  • Medical device manufacturing
  • Renal replacement therapy

Where Byonyks Medical Devices, Inc. is headquartered

Location

Headquarters

HQ city
Itasca
HQ country
United States
HQ region
North America

Offices6 records

Markets served

Byonyks Medical Devices, Inc. business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Medical Device Sales: Sale of X-1 APD Cycler and future X2 & X3 devices for home peritoneal dialysis. The devices are sold directly to healthcare providers and dialysis centers.
  2. Consumables and Dialysate: Recurring revenue from consumables including dialysate solutions and tubing for dialysis treatments. The company is also developing on-demand dialysate production technology.
  3. Overseas Licensing: Revenue from licensing the technology internationally, demonstrated by 10,000+ successful therapies through overseas licenses.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goSEC filing indicates minimum investment of $25,000

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Byonyks Medical Devices, Inc. product offering

Product offering

Core offering

Byonyks Medical Devices designs, manufactures, and distributes the FDA 510(k)-cleared X-1 Automated Peritoneal Dialysis (APD) Cycler for home-based treatment of end-stage kidney disease. The device delivers bloodless, needle-free dialysis with a touchscreen interface, battery backup, and integrated safety systems, targeting dialysis providers, nephrologists, and healthcare systems. The company is also developing next-generation X2 and X3 devices featuring biocompatible, toxin-free dialysate and on-demand dialysate production technology.

Product overview

Byonyks Medical Devices, Inc. is a medical device company focused on home-based peritoneal dialysis solutions. The company has developed the X-1 APD Cycler as its flagship FDA 510(k)-cleared product, an automated peritoneal dialysis machine designed for home use that offers needle-free, bloodless dialysis therapy. The company is also developing X2 and X3 devices as next-generation products to further advance peritoneal dialysis technology. Together, these products aim to disrupt the $120 billion dialysis industry by offering more affordable, patient-friendly, and biocompatible dialysis solutions.

Differentiator

Problem solved

Functional benefit

Products and services

  • Byonyks X-1 APD Cycler FDA 510(k)-cleared automated peritoneal dialysis (APD) cycler designed for home use by ESKD patients. Warms dialysis fluid to body temperature, operates needle-free, includes battery backup for uninterrupted therapy, features a touchscreen interface with built-in safety systems (pressure monitoring, leak detection, intelligent alarms, emergency stop), and is sold to dialysis providers, hospitals, and home dialysis programs.
  • Byonyks X2 & X3 Next-Generation Peritoneal Dialysis Devices Next-generation peritoneal dialysis devices in development designed to deliver ultra-pure, biocompatible, non-inflammatory dialysis solutions. The combination of X2 and X3 devices is intended to reduce proven inflammatory mediators, allow customization of glucose and bicarbonate concentrations, reduce peritonitis risk, and significantly reduce plastic medical waste compared to typical home PD systems.
  • Dialysate Solutions and Dialysis Consumables Recurring consumables for dialysis treatments, including dialysate solutions and tubing used with the X-1 APD Cycler. Includes development of on-demand dialysate production technology aimed at lowering per-treatment cost and supporting home PD adoption in markets with limited supply chains.
  • Overseas Dialysis Technology Licensing International licensing of Byonyks' dialysis technology to regional partners and distributors, evidenced by 10,000+ successful therapies delivered through overseas licenses before U.S. commercialization. Provides access to South Asia, Middle East, East Africa, and European markets where APD availability has historically been limited.

Quantifiable outcome

  • 10% higher survival rate with peritoneal dialysis vs in-center hemodialysis (U.S. Renal Data System)
  • +3 more outcomes

Companies that use Byonyks Medical Devices, Inc.

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Byonyks Medical Devices, Inc. technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Byonyks Medical Devices, Inc. partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • Home Dialysis TherapiescoreStrategic or Co-development PartnerDr. Andrew King, Byonyks' Chief Medical Officer for North America, founded Home Dialysis Therapies in San Diego. This partnership provides clinical expertise and early adopter validation for Byonyks' APD technology, with Denise Barnes R.N. helping establish home-only facilities under this partnership.
  • Kidney Beyond BordersminorStrategic or Co-development PartnerPartnership with Dr. Irfan Munir, Founder & President of Kidney Beyond Borders, for expanding access to dialysis care globally through collaborative initiatives and shared learning.
  • SGS (Geneva)coreTechnology or IntegrationObtained official IEC certification from SGS in October 2023, an essential regulatory milestone for international market access and product safety compliance.
  • TUV SUD MinnesotacoreTechnology or IntegrationObtained IEC approval from TUV SUD Minnesota in 2023, supporting regulatory compliance for the X-1 APD Cycler.
  • FiLab (France)coreTechnology or IntegrationFiLab France approved biocompatibility tests in July 2023, a critical step in regulatory approval process for medical devices.
  • HTW (China)coreTechnology or IntegrationHTW China electrical testing lab approved in September 2023, supporting global regulatory compliance for the X-1 device.

Scale indicators9 records

Recent moves9 records

Expansion highlights6 records

Byonyks Medical Devices, Inc. competitors and assessment

Company assessment

Direct peers

  • Baxter International: Baxter is the dominant U.S. APD cycler manufacturer (HomeChoice, Amia systems) and the primary incumbent Byonyks must displace. Same product category (home peritoneal dialysis cyclers), same target customers (dialysis providers, nephrologists, ESKD patients), and overlapping direct-sales channels to hospitals and clinics.
  • Fresenius Medical Care: Fresenius manufactures the sleep.safe harmony APD cycler and operates the largest U.S. dialysis clinic network (FMCNA), making it both a direct device competitor and a captive customer ecosystem. Directly comparable on product, market, and end-user.

Emerging players

  • Outset Medical: Outset Medical's Tablo is a home-use hemodialysis system targeting the same shift to home-based renal care that Byonyks addresses. While hemodialysis rather than peritoneal, both pursue home dialysis economics, payer reform incentives, and inpatient-to-home care migration.
  • Quanta Dialysis Technologies: Quanta develops a portable hemodialysis device (SC+) for home and clinic use, targeting the same broader market of patients seeking home-based renal replacement therapy. Comparable on mission and home dialysis focus though different modality (HD vs PD).
  • DEKA Research & Development: DEKA partnered with Baxter on APD technology and continues to develop next-generation peritoneal and hemodialysis systems. It represents the type of engineering-driven entrant pursuing innovation in the home dialysis category.

Broad incumbents

  • DaVita: DaVita is the largest U.S. dialysis services provider with extensive home dialysis programs. As a key customer of APD cyclers, it is a primary target buyer for Byonyks' X-1 system and benefits from the same regulatory and policy tailwinds.
  • B. Braun: B. Braun manufactures the dialog+ hemodialysis system and offers peritoneal dialysis consumables and equipment. While more diversified, B. Braun competes in the renal care space and is a relevant incumbent across PD and HD products.
  • NxStage Medical (Fresenius): NxStage pioneered home hemodialysis (System One) and is now part of Fresenius. It represents the home dialysis shift that Byonyks also targets and competes with for clinical mindshare and home dialysis program adoption.
  • U.S. Renal Care: U.S. Renal Care is a mid-sized dialysis services provider with growing home dialysis programs, making it a target customer for Byonyks' X-1 cycler and a comparable channel partner in the shift toward home-based renal care.

Regional players

  • Terumo: Terumo offers peritoneal dialysis products and dialysate solutions in Asia and other international markets, overlapping with Byonyks' overseas licensing footprint and serving comparable ESKD patient populations in geographies where the U.S. company is also expanding.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Byonyks Medical Devices, Inc. social profiles

Digital presence

Byonyks Medical Devices, Inc. compliance and trust

Trust signal

Compliance3 records

Byonyks Medical Devices, Inc. financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Byonyks Medical Devices, Inc. leadership team

Management profile

Number of profiles

Profiles15 records

Byonyks Medical Devices, Inc. funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Byonyks Medical Devices, Inc. M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Byonyks Medical Devices, Inc.

What does Byonyks Medical Devices, Inc. do?

Byonyks Medical Devices designs, manufactures, and distributes the FDA 510(k)-cleared X-1 Automated Peritoneal Dialysis (APD) Cycler for home-based treatment of end-stage kidney disease. The device delivers bloodless, needle-free dialysis with a touchscreen interface, battery backup, and integrated safety systems, targeting dialysis providers, nephrologists, and healthcare systems. The company is also developing next-generation X2 and X3 devices featuring biocompatible, toxin-free dialysate and on-demand dialysate production technology.

Is Byonyks Medical Devices, Inc. a public or private company?

Byonyks Medical Devices, Inc. is a private company. It is classified as venture growth investor backed and is currently operating.

When was Byonyks Medical Devices, Inc. founded?

Byonyks Medical Devices, Inc. was founded in 2019. It employs 51 to 100 people.

Where is Byonyks Medical Devices, Inc. based?

Byonyks Medical Devices, Inc. is headquartered in Itasca, United States, in the North America region.

How does Byonyks Medical Devices, Inc. make money?

Three revenue lines are on record. Medical Device Sales are the primary driver. The others are consumables and Dialysate and overseas Licensing.

Who are Byonyks Medical Devices, Inc.'s main competitors?

Direct peers on record are Baxter International and Fresenius Medical Care. Emerging players are Outset Medical, Quanta Dialysis Technologies and DEKA Research & Development. Broad incumbents are DaVita, B. Braun, NxStage Medical (Fresenius) and U.S. Renal Care. Terumo is listed as a regional player.

Does Byonyks Medical Devices, Inc. have an API?

No public API is recorded for Byonyks Medical Devices, Inc..

What industry is Byonyks Medical Devices, Inc. in?

Byonyks Medical Devices, Inc.'s product category is Medical Devices. Its primary akta.pro industry code is HLAHAKAB, Peritoneal Dialysis (PD) Systems & Supplies, with a secondary code of HLAHAKAG, Home Dialysis Equipment & Remote Monitoring. Its NAICS code is 339113 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals